FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995379743> ?p ?o ?g. }

• W1995379743 endingPage "351" @default.
• W1995379743 startingPage "343" @default.
• W1995379743 abstract "National asthma treatment guidelines recommend either the use of inhaled corticosteroids (ICS) or ICS in combination with a long-acting bronchodilator for the treatment of moderate to severe asthma. Even though asthma is common among older adults, few studies have assessed the differences in effectiveness between these two recommended therapies in patients over 65 years of age. The aim of this study was to assess the association of the fluticasone-salmeterol combination (FSC) or ICS initiation on asthma-related events in Medicare-eligible asthma patients. This was a retrospective observational study using a large health claims database (July 1, 2001 to June 30, 2008). Subjects 65 to 79 years of age with 12-month preindex and 3- to 12-month postindex eligibility, an asthma diagnosis (ICD-493.xx), and with 1 or more FSC or ICS claims at index were included. Subjects with an FSC or ICS claim in the preindex and any claim for chronic obstructive pulmonary disease were excluded. Subjects were observed until they had an event (emergency department [ED] inpatient hospitalization [IP], combined IP/ED or oral corticosteroid [OCS] use) or were no longer eligible in the database, whichever came first. Cox proportional hazards regression was used to assess risk of an asthma-related event (IP, ED, or IP/ED). Baseline characteristics (age, sex, region, index season, comorbidities, preindex use of short-acting β-agonists, OCS, other asthma controllers, and asthma-related ED/IP visits) were independent covariates in the model. A total of 10,837 met the criteria (4843 ICS and 5994 FSC). Age (70.4 and 70.5 years, respectively) and the percentage of female subjects (65.5% and 64.8%, respectively) were similar. Asthma-related events were also similar at baseline. Postindex unadjusted rates occurring after >30 days were ED (1.8% vs 1.5%, P = 0.18), IP (2.7% vs 1.7%, P < 0.001), and ED/IP (4.1% vs 2.8%, P < 0.001) for ICS and FSC, respectively. Subjects who received FSC were associated with a 32% (adjusted HR = 0.68; 95% CI, 0.51–0.91) lower risk of experiencing an IP visit and a 22% (HR = 0.78; 95% CI, 0.62–0.98) lower risk of experiencing an ED/IP visit. No differences were observed for ED visits (HR = 0.94; 95% CI, 0.68–1.29). In Medicare-eligible asthma patients, FSC use was associated with lower rates of asthma-related serious exacerbations compared with ICS." @default.
• W1995379743 created "2016-06-24" @default.
• W1995379743 creator A5003851805 @default.
• W1995379743 creator A5017647473 @default.
• W1995379743 creator A5020012431 @default.
• W1995379743 creator A5028196637 @default.
• W1995379743 creator A5053240270 @default.
• W1995379743 date "2012-12-01" @default.
• W1995379743 modified "2023-10-02" @default.
• W1995379743 title "Effect of Combination Fluticasone Propionate and Salmeterol or Inhaled Corticosteroids on Asthma-Related Outcomes in a Medicare-Eligible Population" @default.
• W1995379743 cites W1946607305 @default.
• W1995379743 cites W1982336794 @default.
• W1995379743 cites W1987062528 @default.
• W1995379743 cites W1995554314 @default.
• W1995379743 cites W2013037468 @default.
• W1995379743 cites W2017752389 @default.
• W1995379743 cites W2022235585 @default.
• W1995379743 cites W2028355711 @default.
• W1995379743 cites W2032448234 @default.
• W1995379743 cites W2032809044 @default.
• W1995379743 cites W2051791830 @default.
• W1995379743 cites W2057780602 @default.
• W1995379743 cites W2068195088 @default.
• W1995379743 cites W2098633046 @default.
• W1995379743 cites W2106399406 @default.
• W1995379743 cites W2113995019 @default.
• W1995379743 cites W2122119235 @default.
• W1995379743 cites W2126508434 @default.
• W1995379743 cites W2134263489 @default.
• W1995379743 cites W2141711708 @default.
• W1995379743 cites W2144757555 @default.
• W1995379743 cites W2157546668 @default.
• W1995379743 cites W2163044158 @default.
• W1995379743 cites W4235755338 @default.
• W1995379743 cites W4255052091 @default.
• W1995379743 cites W44183832 @default.
• W1995379743 doi "https://doi.org/10.1016/j.amjopharm.2012.09.005" @default.
• W1995379743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23083688" @default.
• W1995379743 hasPublicationYear "2012" @default.
• W1995379743 type Work @default.
• W1995379743 sameAs 1995379743 @default.
• W1995379743 citedByCount "11" @default.
• W1995379743 countsByYear W19953797432014 @default.
• W1995379743 countsByYear W19953797432015 @default.
• W1995379743 countsByYear W19953797432016 @default.
• W1995379743 countsByYear W19953797432017 @default.
• W1995379743 countsByYear W19953797432018 @default.
• W1995379743 countsByYear W19953797432019 @default.
• W1995379743 countsByYear W19953797432020 @default.
• W1995379743 crossrefType "journal-article" @default.
• W1995379743 hasAuthorship W1995379743A5003851805 @default.
• W1995379743 hasAuthorship W1995379743A5017647473 @default.
• W1995379743 hasAuthorship W1995379743A5020012431 @default.
• W1995379743 hasAuthorship W1995379743A5028196637 @default.
• W1995379743 hasAuthorship W1995379743A5053240270 @default.
• W1995379743 hasConcept C118552586 @default.
• W1995379743 hasConcept C126322002 @default.
• W1995379743 hasConcept C167135981 @default.
• W1995379743 hasConcept C187212893 @default.
• W1995379743 hasConcept C194828623 @default.
• W1995379743 hasConcept C2776042228 @default.
• W1995379743 hasConcept C2776719499 @default.
• W1995379743 hasConcept C2776804153 @default.
• W1995379743 hasConcept C2779028295 @default.
• W1995379743 hasConcept C2780724011 @default.
• W1995379743 hasConcept C2781018748 @default.
• W1995379743 hasConcept C2781212218 @default.
• W1995379743 hasConcept C2908647359 @default.
• W1995379743 hasConcept C71924100 @default.
• W1995379743 hasConcept C99454951 @default.
• W1995379743 hasConceptScore W1995379743C118552586 @default.
• W1995379743 hasConceptScore W1995379743C126322002 @default.
• W1995379743 hasConceptScore W1995379743C167135981 @default.
• W1995379743 hasConceptScore W1995379743C187212893 @default.
• W1995379743 hasConceptScore W1995379743C194828623 @default.
• W1995379743 hasConceptScore W1995379743C2776042228 @default.
• W1995379743 hasConceptScore W1995379743C2776719499 @default.
• W1995379743 hasConceptScore W1995379743C2776804153 @default.
• W1995379743 hasConceptScore W1995379743C2779028295 @default.
• W1995379743 hasConceptScore W1995379743C2780724011 @default.
• W1995379743 hasConceptScore W1995379743C2781018748 @default.
• W1995379743 hasConceptScore W1995379743C2781212218 @default.
• W1995379743 hasConceptScore W1995379743C2908647359 @default.
• W1995379743 hasConceptScore W1995379743C71924100 @default.
• W1995379743 hasConceptScore W1995379743C99454951 @default.
• W1995379743 hasIssue "6" @default.
• W1995379743 hasLocation W19953797431 @default.
• W1995379743 hasLocation W19953797432 @default.
• W1995379743 hasOpenAccess W1995379743 @default.
• W1995379743 hasPrimaryLocation W19953797431 @default.
• W1995379743 hasRelatedWork W1969372887 @default.
• W1995379743 hasRelatedWork W2027063153 @default.
• W1995379743 hasRelatedWork W2038694240 @default.
• W1995379743 hasRelatedWork W2092793338 @default.
• W1995379743 hasRelatedWork W2104662004 @default.
• W1995379743 hasRelatedWork W2116173647 @default.
• W1995379743 hasRelatedWork W2126508434 @default.
• W1995379743 hasRelatedWork W2133801069 @default.

• next